Harbin Gloria Pharmaceuticals (002437.SZ) intends to transfer 20.64% equity of Yuheng Biotechnology. The proceeds will be used to repay the company's debt to Harbin Gloria Pharmaceuticals.

Harbin Gloria Pharmaceuticals (002437.SZ) announced that the company plans to resolve the debt dispute with Qingdao Pushengpuli Enterprise Management Center (Limited Partnership) ("Pushengpuli") regarding the equity transfer payment of Guangzhou Yuheng Bio-Technology Co., Ltd. by signing the "Agreement of Guangzhou Yuheng Bio-Technology Co., Ltd.". The announcement will include the specific background, content, impact, and risks of the company. The lawsuit between the company and Pushengpuli regarding the equity transfer payment of Yuheng Bio-Technology has entered the execution stage. The following process will involve the evaluation of Yuheng Bio-Technology's equity, judicial auction, transfer, payment, and various other procedures, which are cumbersome and time-consuming. Additionally, the evaluation and pricing of Yuheng Bio-Technology's equity face significant difficulties. Selling Yuheng Bio-Technology's equity and recovering the equity transfer payment through regular judicial procedures have a high level of uncertainty. Pushengpuli plans to transfer its 20.64% equity in Yuheng Bio-Technology to Youpeng Bio-Technology (Hainan) Co., Ltd. ("Youpeng Bio-Technology") and use the related payment to repay the debt owed to the company by Pushengpuli.